Rockwell Medical

Rank#10584

Market Cap34.78M

CountryUnited States

Summary

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

History

Rockwell Medical was founded in 1996 and headquartered in Wixom, Michigan. It began commercial manufacturing of dialysis concentrates at Michigan facility in 1997. In 2005, Rockwell acquired rights to Triferic from the University of Michigan. In 2017, the company opened drug manufacturing facility to produce injectable drug and distributes to over 18 countries worldwide.

Mission

Our mission is to improve the lives of those affected by renal disease by providing innovative and unique therapies that prevent, treat, and cure the complications of kidney disease and that are essential for optimal dialysis health.

Vision

Our vision is to drive growth through increased product awareness and utilization, a larger and more presence in major markets, and innovative solutions to improve the lives of those impacted by Renal Disease.

References

https://en.wikipedia.org/wiki/Rockwell_Medical

https://in.investing.com/equities/rockwell-medical

https://finance.yahoo.com/quote/RMTI/profile?p=RMTI

https://www.crunchbase.com/organization/rockwell-medical

https://companiesmarketcap.com/

https://www.rockwellmed.com

Leadership team

Dr. Mark Strobeck Ph.D. (Pres, CEO & Director)

Mr. Paul E. McGarry (SVP of Fin. & Chief Accounting Officer)

Ms. Megan C. Timmins (Exec. VP, Chief Legal Officer & Sec.)

Products / Services